Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

NCT05014776 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Tadalafil
DRUG: Pembrolizumab
DRUG: Ipilimumab
DRUG: CRS-207

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]